Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Transcription Factor-Directed Re-wiring of Chromatin Architecture for Somatic Cell Nuclear Reprogramming toward trans-Differentiation.

Dall'Agnese A, Caputo L, Nicoletti C, di Iulio J, Schmitt A, Gatto S, Diao Y, Ye Z, Forcato M, Perera R, Bicciato S, Telenti A, Ren B, Puri PL.

Mol Cell. 2019 Aug 20. pii: S1097-2765(19)30591-X. doi: 10.1016/j.molcel.2019.07.036. [Epub ahead of print]

PMID:
31519520
2.

Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life.

Henderson MA, Gyorki D, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF.

Ann Surg Oncol. 2019 Sep 12. doi: 10.1245/s10434-019-07810-0. [Epub ahead of print]

PMID:
31515719
3.

Functional characterization of 3D protein structures informed by human genetic diversity.

Hicks M, Bartha I, di Iulio J, Venter JC, Telenti A.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8960-8965. doi: 10.1073/pnas.1820813116. Epub 2019 Apr 15.

4.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

5.

The human noncoding genome defined by genetic diversity.

di Iulio J, Bartha I, Wong EHM, Yu HC, Lavrenko V, Yang D, Jung I, Hicks MA, Shah N, Kirkness EF, Fabani MM, Biggs WH, Ren B, Venter JC, Telenti A.

Nat Genet. 2018 Mar;50(3):333-337. doi: 10.1038/s41588-018-0062-7. Epub 2018 Feb 26.

PMID:
29483654
6.

Human gene essentiality.

Bartha I, di Iulio J, Venter JC, Telenti A.

Nat Rev Genet. 2018 Jan;19(1):51-62. doi: 10.1038/nrg.2017.75. Epub 2017 Oct 30. Review.

PMID:
29082913
7.

BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.

Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ, Roberts JM, Zeid R, Scott TG, Paulk J, Lachance K, Olson CM, Dastjerdi S, Bauer S, Lin CY, Gray NS, Kelliher MA, Churchman LS, Bradner JE.

Mol Cell. 2017 Jul 6;67(1):5-18.e19. doi: 10.1016/j.molcel.2017.06.004. Epub 2017 Jun 29.

8.

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group.

J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3.

PMID:
28368672
9.

Deep sequencing of 10,000 human genomes.

Telenti A, Pierce LC, Biggs WH, di Iulio J, Wong EH, Fabani MM, Kirkness EF, Moustafa A, Shah N, Xie C, Brewerton SC, Bulsara N, Garner C, Metzker G, Sandoval E, Perkins BA, Och FJ, Turpaz Y, Venter JC.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11901-11906. Epub 2016 Oct 4.

10.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group.

Lancet Haematol. 2015 Sep;2(9):e357-66. doi: 10.1016/S2352-3026(15)00115-5. Epub 2015 Aug 20.

PMID:
26685769
11.

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.

Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF.

Lancet Oncol. 2015 Sep;16(9):1049-1060. doi: 10.1016/S1470-2045(15)00187-4. Epub 2015 Jul 20.

PMID:
26206146
12.

Native elongating transcript sequencing reveals human transcriptional activity at nucleotide resolution.

Mayer A, di Iulio J, Maleri S, Eser U, Vierstra J, Reynolds A, Sandstrom R, Stamatoyannopoulos JA, Churchman LS.

Cell. 2015 Apr 23;161(3):541-554. doi: 10.1016/j.cell.2015.03.010.

13.

Bioinformatics and HIV latency.

Ciuffi A, Mohammadi P, Golumbeanu M, di Iulio J, Telenti A.

Curr HIV/AIDS Rep. 2015 Mar;12(1):97-106. doi: 10.1007/s11904-014-0240-x. Review.

14.

A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.

Bradstock KF, Link E, Collins M, Di Iulio J, Lewis ID, Schwarer A, Enno A, Marlton P, Hahn U, Szer J, Cull G, Seymour JF; Australasian Leukaemia and Lymphoma Group.

Br J Haematol. 2014 Dec;167(5):618-25. doi: 10.1111/bjh.13086. Epub 2014 Aug 21.

PMID:
25142189
15.

Dynamics of HIV latency and reactivation in a primary CD4+ T cell model.

Mohammadi P, di Iulio J, Muñoz M, Martinez R, Bartha I, Cavassini M, Thorball C, Fellay J, Beerenwinkel N, Ciuffi A, Telenti A.

PLoS Pathog. 2014 May 29;10(5):e1004156. doi: 10.1371/journal.ppat.1004156. eCollection 2014 May.

16.

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.

Lubomirov R, Arab-Alameddine M, Rotger M, Fayet-Mello A, Martinez R, Guidi M, di Iulio J, Cavassini M, Günthard HF, Furrer H, Marzolini C, Bernasconi E, Calmy A, Buclin T, Decosterd LA, Csajka C, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2013 Jan;23(1):9-18. doi: 10.1097/FPC.0b013e32835ade82.

PMID:
23111422
17.

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group.

Blood. 2012 Aug 23;120(8):1570-80; quiz 1752. Epub 2012 Jun 19.

18.

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF.

Lancet Oncol. 2012 Jun;13(6):589-97. doi: 10.1016/S1470-2045(12)70138-9. Epub 2012 May 9.

PMID:
22575589
19.

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.

Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C; Swiss HIV Cohort Study Group.

Antimicrob Agents Chemother. 2012 Jun;56(6):2959-66. doi: 10.1128/AAC.05424-11. Epub 2012 Feb 27.

20.

Genetic variations in IL28B and allergic disease in children.

Gaudieri S, Lucas M, Lucas A, McKinnon E, Albloushi H, Rauch A, di Iulio J, Martino D, Prescott SL, Tulic MK.

PLoS One. 2012;7(1):e30607. doi: 10.1371/journal.pone.0030607. Epub 2012 Jan 25.

21.

Pharmacogenomics: what is next?

di Iulio J, Rotger M.

Front Pharmacol. 2012 Jan 13;2:86. doi: 10.3389/fphar.2011.00086. eCollection 2011.

22.

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.

Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group.

Haematologica. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506. Epub 2011 Oct 11.

23.

Successful efavirenz dose reduction guided by therapeutic drug monitoring.

Fayet Mello A, Buclin T, Decosterd LA, Delhumeau C, di Iulio J, Fleurent A, Schneider MP, Cavassini M, Telenti A, Hirschel B, Calmy A.

Antivir Ther. 2011;16(2):189-97. doi: 10.3851/IMP1742.

PMID:
21447868
24.

Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.

di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Günthard HF, Battegay M, Bernasconi E, Schmid P, Hirschel B, Barnes E, Klenerman P, Telenti A, Rauch A; Swiss HIV Cohort Study.

Hepatology. 2011 May;53(5):1446-54. doi: 10.1002/hep.24263.

25.

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.

Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, Furrer H, Günthard HF, Telenti A; Swiss HIV Cohort Study.

J Infect Dis. 2011 Jan 15;203(2):246-57. doi: 10.1093/infdis/jiq043. Epub 2010 Dec 9.

26.

Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreak.

Merani S, Petrovic D, James I, Chopra A, Cooper D, Freitas E, Rauch A, di Iulio J, John M, Lucas M, Fitzmaurice K, McKiernan S, Norris S, Kelleher D, Klenerman P, Gaudieri S.

Hepatology. 2011 Feb;53(2):396-405. doi: 10.1002/hep.24076. Epub 2011 Jan 18.

27.

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer.

Day FL, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg JR, Rischin D, McKendick J, Milner AD, Di Iulio J, Matera A, Michael M.

Br J Cancer. 2011 Jan 18;104(2):265-71. doi: 10.1038/sj.bjc.6606051. Epub 2010 Dec 14.

28.

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.

Neely M, Decosterd L, Fayet A, Lee JS, Margol A, Kanani M, di Iulio J, von Schoen-Angerer T, Jelliffe R, Calmy A.

Antimicrob Agents Chemother. 2010 Nov;54(11):4619-25. doi: 10.1128/AAC.00712-10. Epub 2010 Sep 7.

29.

Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group.

Leong T, Joon DL, Willis D, Jayamoham J, Spry N, Harvey J, Di Iulio J, Milner A, Mann GB, Michael M.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):690-5. doi: 10.1016/j.ijrobp.2009.11.042. Epub 2010 May 14.

PMID:
20472363
30.

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.

Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2010 Apr;20(4):217-30. doi: 10.1097/FPC.0b013e328336eee4.

PMID:
20139798
31.

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.

Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study.

Gastroenterology. 2010 Apr;138(4):1338-45, 1345.e1-7. doi: 10.1053/j.gastro.2009.12.056. Epub 2010 Jan 11.

PMID:
20060832
32.

Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers.

Antill YC, Mitchell G, Johnson SA, Devereux L, Milner A, Di Iulio J, Lindeman GJ, Kirk J, Phillips KA, Campbell IG.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):265-74. doi: 10.1158/1055-9965.EPI-09-0359.

33.

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.

di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Günthard HF, Colombo S, Csajka C, Eap CB, Decosterd LA, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2009 Apr;19(4):300-9. doi: 10.1097/FPC.0b013e328328d577.

PMID:
19238117
34.

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.

Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd LA, Eap CB, Biollaz J, Telenti A, Csajka C; Swiss HIV Cohort Study.

Clin Pharmacol Ther. 2009 May;85(5):485-94. doi: 10.1038/clpt.2008.271. Epub 2009 Feb 18.

PMID:
19225447
35.
36.

Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study.

Manoharan A, Reynolds J, Matthews J, Baxter H, Di Iulio J, Leahy M, Juneja S; Australasian Leukaemia and Lymphoma Group.

Drugs Aging. 2007;24(6):481-8.

PMID:
17571913
37.

A randomized, double-blind, crossover trial of the effect of oxygen on dyspnea in patients with advanced cancer.

Philip J, Gold M, Milner A, Di Iulio J, Miller B, Spruyt O.

J Pain Symptom Manage. 2006 Dec;32(6):541-50.

PMID:
17157756
38.

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

Michael M, Thompson M, Hicks RJ, Mitchell PL, Ellis A, Milner AD, Di Iulio J, Scott AM, Gurtler V, Hoskins JM, Clarke SJ, Tebbut NC, Foo K, Jefford M, Zalcberg JR.

J Clin Oncol. 2006 Sep 10;24(26):4228-35. Epub 2006 Aug 8.

PMID:
16896007
39.

Screening behavior in women at increased familial risk for breast cancer.

Antill YC, Reynolds J, Young MA, Kirk JA, Tucker KM, Bogtstra TL, Wong SS, Dudding TE, Di Iulio JL, Phillips KA.

Fam Cancer. 2006;5(4):359-68. Epub 2006 Jul 7.

PMID:
16817030
40.

Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation.

Mitchell G, Antill YC, Murray W, Kirk J, Salisbury E, Lindeman GJ, Di Iulio J, Milner AD, Devereaux L, Phillips KA.

Breast Cancer Res. 2005;7(6):R1122-31. Epub 2005 Nov 14.

41.

Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer.

Antill Y, Reynolds J, Young MA, Kirk J, Tucker K, Bogtstra T, Wong S, Dudding T, Di Iulio J, Phillips KA.

Eur J Cancer. 2006 Mar;42(5):621-8. Epub 2006 Jan 24.

PMID:
16434187
42.

Optimization of a pharmacophore model for 5-HT4 agonists using CoMFA and receptor based alignment.

Iskander MN, Leung LM, Buley T, Ayad F, Di Iulio J, Tan YY, Coupar IM.

Eur J Med Chem. 2006 Jan;41(1):16-26. Epub 2005 Nov 15.

PMID:
16293350
43.

Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.

Campbell B, Wirth A, Milner A, Di Iulio J, MacManus M, Ryan G.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1538-45. Epub 2005 Aug 25.

PMID:
16125872
44.

Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.

Grigg AP, Reynolds J, McQuillan A, Juneja SK, Di Iulio J, Hui C, Smith C, Kimber R, Bradstock KF; Australasian Leukaemia and Lymphoma Group.

Leuk Lymphoma. 2005 Mar;46(3):367-75.

PMID:
15621826
45.

Effects of tachykinins and 5-hydroxytryptamine on intestinal secretion.

Coupar IM, Di Iulio JL.

Clin Exp Pharmacol Physiol. 2003 Oct;30(10):764-8.

PMID:
14516416
46.

Human placental nitric oxide synthase activity is not altered in diabetes.

Di Iulio JL, Gude NM, King RG, Li CG, Rand MJ, Brennecke SP.

Clin Sci (Lond). 1999 Jul;97(1):123-8.

PMID:
10369805
47.

Effects of ATP, ADP, thrombin, vasopressin and U46619 on human placental nitric oxide synthase activity.

Di Iulio JL, Gude NM, Brennecke SP, King RG.

Methods Find Exp Clin Pharmacol. 1997 Oct;19(8):509-14.

PMID:
9442472
48.

Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs.

Najbar-Kaszkiel AT, Di Iulio JL, Li CG, Rand MJ.

Eur J Pharmacol. 1997 Oct 22;337(2-3):251-8.

PMID:
9430422
49.

Determination of nitric oxide synthase activity in rat, pig and rabbit prostate glands.

Di Iulio JL, Li CG, Rand MJ.

Eur J Pharmacol. 1997 Oct 22;337(2-3):245-9.

PMID:
9430421
50.

Reduction of placental nitric oxide synthase activity in pre-eclampsia.

Brennecke SP, Gude NM, Di Iulio JL, King RG.

Clin Sci (Lond). 1997 Jul;93(1):51-5.

PMID:
9279203

Supplemental Content

Loading ...
Support Center